Esperion Therapeutics, Inc. (ESPR)
Pre-Market:
| Previous Close | 1.2400 |
| Open | 1.2500 |
| Bid | 1.2400 x 1100 |
| Ask | 1.2400 x 3200 |
| Day's Range | 1.1490 - 1.3700 |
| 52 Week Range | 1.1200 - 8.8700 |
| Volume | |
| Avg. Volume | 3,284,411 |
| Market Cap | 123.043M |
| Beta (5Y Monthly) | 0.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
American College of Cardiology Program to Increase Cholesterol Screenings
Quality Improvement and Education Program sponsored by Amgen, Esperion to improve adherence to guideline recommendations for managing LDL WASHINGTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- The American College of Cardiology, through a strategic collaboration with Amgen and Esperion, is launching a new quality improvement campaign, “Driving Urgency in LDL Screening,” to increase the rate of diagnostic LDL screening in patients without a prior cardiac event as well as those with known cardiovascular d
- GlobeNewswire
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. Sheldon Koenig, President and Chief Executive Officer, will participate in a corporate presentation on Monday, September 11, 2023 at 3:00 PM ET. The Esperion management team will also host investor meetings that same day. To register for the live webcast, follow this link. A live audio webcast can be accessed on the investo
- GlobeNewswire
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
– In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% risk reduction in MACE-3 – – In an analysis of patients with diabetes, bempedoic acid shows 17% risk reduction in MACE-4 and 20% risk reduction in MACE-3 – – No increase in development of new onset diabetes in patients randomized to bempedoic acid compared to placebo – ANN ARBOR, Mich., Aug. 26, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of results from two o
